- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 864-878 of
1,261 results
2455 Exhibit: EX2455 Adlyxin Prescribing Information rev July 2016
Document
IPR2023-00724, No. 2455 Exhibit - EX2455 Adlyxin Prescribing Information rev July 2016 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2011 Exhibit: EX2011 Declaration of George L Bakris, MD
Document
IPR2023-00724, No. 2011 Exhibit - EX2011 Declaration of George L Bakris, MD (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2456 Exhibit: EX2456 US Food Drug Administration, DrugsFDA, Adlyxin
Document
IPR2023-00724, No. 2456 Exhibit - EX2456 US Food Drug Administration, DrugsFDA, Adlyxin (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2423 Exhibit: EX2423 US Food Drug Administration, DrugsFDA, Jentadueto®
Document
IPR2023-00724, No. 2423 Exhibit - EX2423 US Food Drug Administration, DrugsFDA, Jentadueto® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2112 Exhibit: EX2112 Terry, T, et al, Does aggressive glycemic control benefit mac...
Document
IPR2023-00724, No. 2112 Exhibit - EX2112 Terry, T, et al, Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes Insights from ACCORD, ADVAN...
|
|
Cite Document
2410 Exhibit: EX2410 Novo Nordisk, “Dosing and administering Victoza®,” httpswww...
Document
IPR2023-00724, No. 2410 Exhibit - EX2410 Novo Nordisk, “Dosing and administering Victoza®,” httpswwwnovomedlinkcomdiabetesproductstreatmentsvictoza dosing administrationhtml (P.T.A....
|
|
Cite Document
2518 Exhibit: EX2518 Han, SH, et al, Public Interest in the Off Label Use of Glucag...
Document
IPR2023-00724, No. 2518 Exhibit - EX2518 Han, SH, et al, Public Interest in the Off Label Use of Glucagon like Peptide 1 Agonists Ozempic for Cosmetic Weight Loss A Google Trends Analysis...
|
|
Cite Document
2405 Exhibit: EX2405 US Food Drug Administration, Orange Book Approved Drug ...
Document
IPR2023-00724, No. 2405 Exhibit - EX2405 US Food Drug Administration, Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations, ANDA 205981 (P.T.A.B. Jan. 17, 2...
|
|
Cite Document
... EX2007 Excerpt of Novo Nordisk’s Initial Responses to Defendants’ Initial Invalidity Contentions Regarding US Patent Nos 8,129,343 8,536,122 8,1...
Document
IPR2023-00724, No. 2007 Exhibit - EX2007 Excerpt of Novo Nordisk’s Initial Responses to Defendants’ Initial Invalidity Contentions Regarding US Patent Nos 8,129,343 8,536,122 8,114,833 8...
|
|
Cite Document
1011 Exhibit: WO421
Document
IPR2023-00724, No. 1011 Exhibit - WO421 (P.T.A.B. Mar. 16, 2023)
|
|
Cite Document
1100 Exhibit: Exhibit 1100 Jose
Document
IPR2023-00724, No. 1100 Exhibit - Exhibit 1100 Jose (P.T.A.B. May. 22, 2024)
|
|
Cite Document
1099 Exhibit: Exhibit 1099 Garber 2011b
Document
IPR2023-00724, No. 1099 Exhibit - Exhibit 1099 Garber 2011b (P.T.A.B. May. 22, 2024)
|
|
Cite Document
1311 Exhibit: Exhibit 1311 Redacted Flint Dep
Document
IPR2023-00724, No. 1311 Exhibit - Exhibit 1311 Redacted Flint Dep (P.T.A.B. Jun. 21, 2024)
|
|
Cite Document
1006 Exhibit: Jusko CV
Document
IPR2023-00724, No. 1006 Exhibit - Jusko CV (P.T.A.B. Mar. 16, 2023)
|
|
Cite Document
1007 Exhibit: Dalby Decl
Document
IPR2023-00724, No. 1007 Exhibit - Dalby Decl (P.T.A.B. Mar. 16, 2023)
|
|
Cite Document
